ModernMedicine Resource Center More Topics


How pharmacists can keep up with biosimilar approvalsThe Food and Drug Administration (FDA) has released its lists of approved biosimilar licensed products, called the “Purple Book”. The invaluable site includes the date a biological product was licensed under the PHS Act and whether FDA evaluated the biological product for reference product exclusivity.
Independents voice concern about low generic paymentsInadequate reimbursement rates are threatening patient access to generic drugs and to community pharmacies, according to a recent survey by the National Community Pharmacists Association (NCPA).
Sam’s Club provides greater savings on generic drugsSam’s Club is offering greater discounts and some free generic medications with an expanded prescription program for its Plus and Business Plus members.
FDA reopens comment period on proposal for generic labeling changesShould generic drug makers be required to update their drug labels about safety concerns before FDA reviews the change? Should this be done even if the information differs from the brand name drug labels temporarily?
Generic shortages complicating pharmacists’ dutiesAs healthcare facilities across the nation deal with shortages of certain drugs, including generics, pharmacists and pharmacy managers are tasked with the daily monitoring of drug supplies and increased communications with other healthcare professionals such as nurses and physicians.
FDA approves first generic version of NexiumFDA approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules, Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA) to treat gastroesophageal reflux disease (GERD) in adults and children aged 1 year and older. Esomeprazole is a proton pump inhibitor that reduces the amount of acid in the stomach.
2014 drug costs soar, no end in sightWhile hepatitis C drugs Solvani, Harvoni, and Viekira Pak have been in the news recently because of their high price tag, and Express Scripts’ and CVS Health’s exclusive agreements with the drugmakers, they are not the only culprits in soaring drug costs.
[BLOG]: Hepatitis C market competition arrives for 2015There is plenty of activity already in the hepatitis C market as competition has arrived for 2015, including CVS Health versus Express Scripts and Gilead Sciences versus AbbVie, over FDA-approved hepatitis C treatments. This will have implications for retail prescriptions as well as continuity-of-care programs within non-Medicare accountable care organizations (ACOs) and health systems.
FDA concerned about generic ADHD drugsFDA has warned about 2 approved generic versions of Concerta tablets to treat attention-deficit hyperactivity disorder (ADHD).
FDA questions effectiveness of two generic versions of ConcertaFDA recently raised concerns that two generic versions of Concerta (methylphenidate hydrochloride extended-release tablets; Janssen Pharmaceuticals) may not be therapeutically equivalent to the brand-name drug.